Author

Stephen D. Schibeci

The University of Sydney

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Genetics· 2 Genomics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 3 Assay:DNA methylation· 3 Organism:human· 3 Approach:statistical model· 3 Research Focus:gene regulatory network inference· 2 Research Focus:GWAS / association mapping· 1 Assay:whole-genome sequencing· 1

Frequent Co-Authors

David Richmond BoothiD· 3 shared Grant Peter ParnelliD· 3 shared Nicole FewingsiD· 3 shared Lawrence T. C. OngiD· 2 shared Ali AfrasiabiiD· 1 shared David Alexander BrowniD· 1 shared Fiona C. McKayiD· 1 shared Graeme J. Stewart· 1 shared

Activity by Year

2018-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersGenetics

David Richmond BoothORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

LINE-1 DNA methylation in response to aging and vitamin D

Lawrence T. C. Ong, Stephen D. Schibeci, Nicole Fewings, David Richmond Booth, Grant Peter Parnell

This study investigates the effects of aging and vitamin D on LINE-1 DNA methylation in haematopoietic progenitors, finding no effect of vitamin D but age-related differences.

bioRxiv · May 2, 2020 · PreprintGenetics

Age-dependent VDR peak DNA methylation as a mechanism for latitude-dependent MS risk

Lawrence T. C. Ong, Stephen D. Schibeci, Nicole Fewings, David Richmond Booth, Grant Peter Parnell

The paper investigates how vitamin D exposure affects DNA methylation at VDR binding sites in myeloid cells, linking age-dependent changes to latitude-related multiple sclerosis risk.

bioRxiv · Apr 27, 2020 · PreprintGenetics

Genetic evidence that the latency III stage of Epstein-Barr Virus infection is a therapeutic target for Multiple Sclerosis

Ali Afrasiabi, Grant Peter Parnell, Nicole Fewings, Stephen D. Schibeci, Monica A. Basuki, Ramya Chandramohan, David Alexander Brown, Sanjay Swaminathan, Fiona C. McKay, Graeme J. Stewart, David Richmond Booth

The paper identifies EBV latency III stage as a therapeutic target for MS by linking MS risk SNPs to EBV transcription factors and miRNAs.

bioRxiv · Aug 13, 2018 · PreprintGenomics